Poor Prognosis With Coexistence Of EGFR T790M Mutation And Common EGFR-Activating Mutation In Non- Small Cell Lung Cancer

PURPOSE: Previous studies have shown that the presence of EGFR T790M mutation may reduce the treatment efficacy of tyrosine kinase inhibitors (TKIs) in EGFR-mutant lung cancer. However, little is known about the clinical features and outcomes of EGFR T790M mutation in pretreated patients with NSCLC....

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Xuejuan, Zhao, Yanfeng, Bao, Yi, Yin, Wei, Liu, Liyu, Liu, Ruchuan, Yu, Zhengquan, Zhou, Xiao, Shuai, Jianwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859090/
https://www.ncbi.nlm.nih.gov/pubmed/32009817
http://dx.doi.org/10.2147/CMAR.S216721

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859090/
https://www.ncbi.nlm.nih.gov/pubmed/32009817
http://dx.doi.org/10.2147/CMAR.S216721

Ejemplares similares